Biotech ETFs in the biology trade
Biotechnology companies, many not yet profitable. Driven by trial results, approvals and what it costs them to raise money.
8ETFs in this category
$26.7bnmoney in them
20.5%of the biology trade’s money
IBBlargest unleveraged ETF, 43.1%
How they did, to Nov 2, 2026
| 1 month | YTD | 12 months | |
|---|---|---|---|
| Category median | +1.1% | +26.6% | +35.2% |
| Its story | +7.5% | +21.0% | +29.0% |
| Broad US ETFs | −2.5% | +11.5% | +11.8% |
Every ETF here, largest first
| # | ETF | Name | Assets | Share | 12 months | Fee |
|---|---|---|---|---|---|---|
| 1 | IBB | iShares Biotechnology ETF | $11.5bn | 43.1% | +34.4% | 0.44% |
| 2 | XBI | SPDR S&P Biotech ETF | $11.0bn | 41.4% | +35.5% | 0.35% |
| 3 | FBT | First Trust NYSE Arca Biotechnology Index Fund | $3.1bn | 11.7% | +41.9% | 0.55% |
| 4 | BBH | VanEck Biotech ETF | $523m | 2.0% | +41.2% | 0.35% |
| 5 | SBIO | ALPS Medical Breakthroughs ETF | $188m | 0.7% | +18.4% | 0.50% |
| 6 | BBP | Virtus LifeSci Biotech Products ETF | $137m | 0.5% | +36.6% | 0.34% |
| 7 | IBBQ | Invesco Nasdaq Biotechnology ETF | $120m | 0.5% | +34.9% | 0.19% |
| 8 | BBC | Virtus LifeSci Biotech Clinical Trials ETF | $35m | 0.1% | +31.6% | 0.65% |
Other categories in the biology trade
Common questions
Which ETFs are biotech ETFs?8 US ETFs sit in this category of the biology trade. Biotechnology companies, many not yet profitable. Driven by trial results, approvals and what it costs them to raise money.
What is the largest biotech ETF?IBB, iShares Biotechnology ETF, with $11.5bn, 43.1% of the category's money.
How have biotech ETFs performed?The median unleveraged ETF here returned +35.2% over the last 12 months to Nov 2, 2026, against +11.8% for broad US ETFs. Past performance, not a forecast.